Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(11):736-747; doi:10.1093/jnci/djj206
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (73)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Grösch, S.
Right arrow Articles by Geisslinger, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grösch, S.
Right arrow Articles by Geisslinger, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press.

REVIEW

Cyclooxygenase-2 (COX-2)–Independent Anticarcinogenic Effects of Selective COX-2 Inhibitors

Sabine Grösch, Thorsten Jürgen Maier, Susanne Schiffmann, Gerd Geisslinger

Affiliation of authors: Pharmazentrum Frankfurt, ZAFES, Institut für klinische Pharmakologie, Klinikum der Johann Wolfgang Goethe–Universität Frankfurt, Theodor Stern Kai 7, Frankfurt/Main, Germany

Correspondence to: Sabine Grösch, PhD, Pharmazentrum Frankfurt, Institut für Klinische Pharmakologie, Klinikum der Johann Wolfgang Goethe-Universität, Theodor Stern Kai 7, 60590 Frankfurt/Main, Germany (e-mail: groesch{at}em.uni-frankfurt.de).

Nonsteroidal antiinflammatory drugs (NSAIDs) appear to reduce the risk of developing cancer. One mechanism through which NSAIDs act to reduce carcinogenesis is to inhibit the activity of cyclooxygenase-2 (COX-2), an enzyme that is overexpressed in various cancer tissues. Overexpression of COX-2 increases cell proliferation and inhibits apoptosis. However, selective COX-2 inhibitors can also act through COX-independent mechanisms. In this review, we describe the COX-2–independent molecular targets of these COX-2 inhibitors and discuss how these targets may be involved in the anticarcinogenic activities of these selective COX-2 inhibitors. We also compare the concentrations of these inhibitors used in in vitro and in vivo experiments and discuss the implications of the in vitro studies for clinical management of cancer with these drugs.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Pathol.Home page
C. D. Keene, R. Chang, C. Stephen, M. Nivison, S. E. Nutt, A. Look, R. M. Breyer, P. J. Horner, R. Hevner, and T. J. Montine
Protection of Hippocampal Neurogenesis from Toll-Like Receptor 4-Dependent Innate Immune Activation by Ablation of Prostaglandin E2 Receptor Subtype EP1 or EP2
Am. J. Pathol., June 1, 2009; 174(6): 2300 - 2309.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Maussang, E. Langemeijer, C. P. Fitzsimons, M. Stigter-van Walsum, R. Dijkman, M. K. Borg, E. Slinger, A. Schreiber, D. Michel, C. P. Tensen, et al.
The Human Cytomegalovirus-Encoded Chemokine Receptor US28 Promotes Angiogenesis and Tumor Formation via Cyclooxygenase-2
Cancer Res., April 1, 2009; 69(7): 2861 - 2869.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Mutter, B. Lu, D. P. Carbone, I. Csiki, L. Moretti, D. H. Johnson, J. D. Morrow, A. B. Sandler, Y. Shyr, F. Ye, et al.
A Phase II Study of Celecoxib in Combination with Paclitaxel, Carboplatin, and Radiotherapy for Patients with Inoperable Stage IIIA/B Non-Small Cell Lung Cancer
Clin. Cancer Res., March 15, 2009; 15(6): 2158 - 2165.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Hu, G. Peluffo, H. Chen, R. Gelman, S. Schnitt, and K. Polyak
Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast
PNAS, March 3, 2009; 106(9): 3372 - 3377.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
G. Heiduschka, B. M. Erovic, L. Vormittag, C. Skoda, H. Martinek, M. Brunner, K. Ehrenberger, and D. Thurnher
7{beta}-Hydroxycholesterol Induces Apoptosis and Regulates Cyclooxygenase 2 in Head and Neck Squamous Cell Carcinoma
Arch Otolaryngol Head Neck Surg, March 1, 2009; 135(3): 261 - 267.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. V. Grau, R. S. Sandler, G. McKeown-Eyssen, R. S. Bresalier, R. W. Haile, E. L. Barry, D. J. Ahnen, J. Gui, R. W. Summers, and J. A. Baron
Nonsteroidal Anti-inflammatory Drug Use After 3 Years of Aspirin Use and Colorectal Adenoma Risk: Observational Follow-up of a Randomized Study
J Natl Cancer Inst, February 18, 2009; 101(4): 267 - 276.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
A. H. Eliassen, W. Y. Chen, D. Spiegelman, W. C. Willett, D. J. Hunter, and S. E. Hankinson
Use of Aspirin, Other Nonsteroidal Anti-inflammatory Drugs, and Acetaminophen and Risk of Breast Cancer Among Premenopausal Women in the Nurses' Health Study II
Arch Intern Med, January 26, 2009; 169(2): 115 - 121.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
S. Schiffmann, J. Sandner, R. Schmidt, K. Birod, I. Wobst, H. Schmidt, C. Angioni, G. Geisslinger, and S. Grosch
The selective COX-2 inhibitor celecoxib modulates sphingolipid synthesis
J. Lipid Res., January 1, 2009; 50(1): 32 - 40.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
C. Olivares, M. Bilotas, R. Buquet, M. Borghi, C. Sueldo, M. Tesone, and G. Meresman
Effects of a selective cyclooxygenase-2 inhibitor on endometrial epithelial cells from patients with endometriosis
Hum. Reprod., December 1, 2008; 23(12): 2701 - 2708.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
N. Fatima, M. Yi, S. Ajaz, R. M. Stephens, S. Stauffer, P. Greenwald, D. J. Munroe, and I. U. Ali
Altered Gene Expression Profiles Define Pathways in Colorectal Cancer Cell Lines Affected by Celecoxib
Cancer Epidemiol. Biomarkers Prev., November 1, 2008; 17(11): 3051 - 3061.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
L. R. Howe and S. M. Lippman
Modulation of Breast Cancer Risk by Nonsteroidal Anti-inflammatory Drugs
J Natl Cancer Inst, October 15, 2008; 100(20): 1420 - 1423.
[Full Text] [PDF]

Home page
 Int J EpidemiolHome page
C Fortes, S Mastroeni, F Melchi, M A Pilla, G Antonelli, D Camaioni, M Alotto, and P Pasquini
A protective effect of the Mediterranean diet for cutaneous melanoma
Int. J. Epidemiol., October 1, 2008; 37(5): 1018 - 1029.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. J. Fidler, A. Argiris, J. D. Patel, D. H. Johnson, A. Sandler, V. M. Villaflor, J. Coon IV, L. Buckingham, K. Kaiser, S. Basu, et al.
The Potential Predictive Value of Cyclooxygenase-2 Expression and Increased Risk of Gastrointestinal Hemorrhage in Advanced Non-Small Cell Lung Cancer Patients Treated with Erlotinib and Celecoxib
Clin. Cancer Res., April 1, 2008; 14(7): 2088 - 2094.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. Torres, C. Paget, J. Fontaine, T. Mallevaey, T. Matsuoka, T. Maruyama, S. Narumiya, M. Capron, P. Gosset, C. Faveeuw, et al.
Prostaglandin D2 Inhibits the Production of IFN-{gamma} by Invariant NK T Cells: Consequences in the Control of B16 Melanoma
J. Immunol., January 15, 2008; 180(2): 783 - 792.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
Y. Feng, J. R. Neale, M. A. Doll, and D. W. Hein
Chemoprevention of Arylamine-Induced Colorectal Aberrant Crypts
Experimental Biology and Medicine, January 1, 2008; 233(1): 71 - 75.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
N. Baryawno, B. Sveinbjornsson, S. Eksborg, A. Orrego, L. Segerstrom, C. O. Oqvist, S. Holm, B. Gustavsson, B. Kagedal, P. Kogner, et al.
Tumor-growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets
Neuro-oncol, January 1, 2008; 10(5): 661 - 674.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. Chen, X. Liu, P. Yue, A. H. Schonthal, F. R. Khuri, and S.-Y. Sun
CCAAT/Enhancer Binding Protein Homologous Protein-Dependent Death Receptor 5 Induction and Ubiquitin/Proteasome-Mediated Cellular FLICE-Inhibitory Protein Down-Regulation Contribute to Enhancement of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by Dimethyl-Celecoxib in Human Non Small-Cell Lung Cancer Cells
Mol. Pharmacol., November 1, 2007; 72(5): 1269 - 1279.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
C. M. Tammemagi, M. T. Freedman, T. R. Church, M. M. Oken, W. G. Hocking, P. A. Kvale, P. Hu, T. L. Riley, L. R. Ragard, P. C. Prorok, et al.
Factors Associated with Human Small Aggressive Non Small Cell Lung Cancer
Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 2082 - 2089.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Mimeault and S. K. Batra
Interplay of distinct growth factors during epithelial mesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies
Ann. Onc., October 1, 2007; 18(10): 1605 - 1619.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Gradilone, F. M. Pulcinelli, L. V. Lotti, S. Martino, T. Mattiello, L. Frati, A. M. Agliano, and P. Gazzaniga
Celecoxib Induces MRP-4 in Lung Cancer Cells: Therapeutic Implications
J. Clin. Oncol., September 20, 2007; 25(27): 4318 - 4320.
[Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. A. Crowell, V. E. Steele, and J. R. Fay
Targeting the AKT protein kinase for cancer chemoprevention
Mol. Cancer Ther., August 1, 2007; 6(8): 2139 - 2148.
[Abstract] [Full Text] [PDF]

Home page
 jvdiHome page
K. M. Rassnick and B. L. Njaa
Cyclooxygenase-2 immunoreactivity in equine ocular squamous-cell carcinoma
J Vet Diagn Invest, July 1, 2007; 19(4): 436 - 439.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
I. Stasinopoulos, D. R. O'Brien, F. Wildes, K. Glunde, and Z. M. Bhujwalla
Silencing of Cyclooxygenase-2 Inhibits Metastasis and Delays Tumor Onset of Poorly Differentiated Metastatic Breast Cancer Cells
Mol. Cancer Res., May 1, 2007; 5(5): 435 - 442.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J.-Y. Liou, D. Ghelani, S. Yeh, and K. K. Wu
Nonsteroidal Anti-inflammatory Drugs Induce Colorectal Cancer Cell Apoptosis by Suppressing 14-3-3{varepsilon}
Cancer Res., April 1, 2007; 67(7): 3185 - 3191.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
D. Schottenfeld and J. Beebe-Dimmer
Alleviating the Burden of Cancer: A Perspective on Advances, Challenges, and Future Directions.
Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2049 - 2055.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B. Ma and A. Chan
Transcriptional profiling of tumor biopsies in oncology trials--a 'window' of opportunity for evaluating new drugs in nasopharyngeal cancer?
Ann. Onc., November 1, 2006; 17(11): 1611 - 1613.
[Full Text] [PDF]

Home page
 JCOHome page
I. Csiki and D. H. Johnson
Did Targeted Therapy Fail Cyclooxygenase Too?
J. Clin. Oncol., October 20, 2006; 24(30): 4798 - 4800.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.